This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?
I read post #121 twice before replying, because I had assumed the opposite.
STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially larger than anything previously achieved pharmacologically.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP 4 (…
|
+6 | 10 | 13k | 28d |
|
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…
|
+126 | 138 | 31k | 17mo |
|
Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-OSA (…
|
+116 | 120 | 23k | 3mo |
|
Journal club: STEP 8 and the fairness of the comparator dose
Journal club: STEP 8 and the fairness of the comparator dose — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 8 ( JAMA , 2022) and finding…
|
+2 | 6 | 39k | 12mo |
|
Journal club: LEADER as the historical anchor
Journal club: LEADER as the historical anchor Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with SURMOUNT-4 ( JAMA , 2024) and…
|
+103 | 110 | 8.1k | 2h |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Citing a preprint in a maintained document: our rule and its reasoning
On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a…
|
2 | 467 | 4mo | |
|
SNAC and the mechanism of oral peptide absorption
On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…
|
+13 | 17 | 14k | 17mo |
|
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold?
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 (…
|
+21 | 25 | 45k | 7mo |
|
Journal club: SURPASS-2 and the semaglutide 1 mg comparator
On the subject in the title: Journal club: SURPASS-2 and the semaglutide 1 mg comparator Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting;…
|
+71 | 76 | 52k | 21mo |
|
Run-in periods and the population they select — the long version
Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please read…
|
2 | 8.9k | 4mo |